Please login to the form below

Not currently logged in
Email:
Password:

IGEM Therapeutics appoints Dr Tim Wilson as CEO

He joins after the UK immuno-oncology firm raises £2m to advance its pipeline

Tim WilsonUK-based immuno-oncology company IGEM - a spin-out of King’s College London - has appointed Dr Tim Wilson as its new chief executive officer at a time when the company has raised £2m from Epidarex Capital, in order to progress its pipeline of IgE antibody drug candidates.

Wilson has over 28 years’ experience in the life sciences sector, ranging from venture capital and start-ups to investment banking and equity research.

He said: “The raising of £2m in series A finding is a testament to the compelling research results generated by Dr Karagiannis and her team at King’s College London.

“I look forward to leading the company as we create important new therapies for the treatment of cancer.”

Wilson has worked for numerous private and public life science companies in the US and Europe at all stages of development, from start-ups to industry leaders.

Dr Peter Finan, venture partner and Epidarex Capital, said: “We are very pleased to have been able to recruit Dr Tim Wilson to lead IGEM as CEO.

“We look forward to working with IGEM to realise their potential.”

21st June 2017

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
JPA Health

JPA Health is an award-winning public relations, marketing and advocacy firm known for sharing our clients’ commitment to making people...

Latest intelligence

Personalised medicine AI
How early-stage clinical research is facilitating the new wave of personalised medicines
By Jorg Taubel...
patient diversity buckland
Patient diversity in clinical trials needs to be centre stage
By Danny Buckland...
Why empathy in digital patient recruitment is vital
This is where empathy mapping can be incredibly effective....